FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.405,66 +470,90 (+1,24%) Petrolio
81,24 -0,69 (-0,84%) Bitcoin EUR
56.889,89 -2.883,58 (-4,82%)
INCY Jun 2024 45.000 call
| Chiusura precedente | 11,20 |
| Aperto | 11,20 |
| Denaro | 6,00 |
| Lettera | 9,60 |
| Prezzo d'esercizio | 45,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 11,20 - 11,20 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 4 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
